You are here

Positive Phase III Results Reported for Abraxane (Paclitaxel) in Metastatic Pancreatic Cancer

Nab-paclitaxel/gemcitabine is more effective than gemcitabine alone (October 16)

Positive results have been reported from the phase III Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) of Abraxane (paclitaxel protein-bound particles for injectable suspension, albumin-bound [nab-paclitaxel]; Celgene International Sàrl) in combination with gemcitabine (Gemzar, Eli Lilly). The new findings were reported online in the New England Journal of Medicine.

The MPACT trial was an open-label randomized study of 861 previously untreated patients with metastatic pancreatic cancer in North America, Europe, and Australia.

The patients were randomly assigned to treatment with nab-paclitaxel and gemcitabine (n = 431) or gemcitabine alone (n = 430). Patients in the nab-paclitaxel/gemcitabine group received nab-paclitaxel as an intravenous (IV) infusion over 30 to 40 minutes at a dose of 125 mg/m2 followed by gemcitabine as an IV infusion over 30 to 40 minutes at a dose of 1,000 mg/m2 given on days 1, 8, and 15 of each 28-day cycle. In the comparator treatment group, gemcitabine monotherapy was administered at a dose of 1,000 mg/m2 given weekly for 7 weeks followed by a 1-week rest period in cycle 1. In cycle 2 and onwards, gemcitabine was administered on days 1, 8, and 15 of a 28-day cycle. The study’s primary endpoint was overall survival (OS).

The median OS was 8.5 months in the nab-paclitaxel/gemcitabine group compared with 6.7 months in the gemcitabine group (hazard ratio [HR] for death, 0.72; P P P

Sources: Celgene; October 16, 2013; and NEJM; October 16, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs